Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEZRULY vs TEZSPIRE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tezrul is a small molecule inhibitor of the human immunodeficiency virus (HIV) integrase enzyme, blocking the integration of viral DNA into the host genome. It also inhibits the HIV protease enzyme at higher concentrations, disrupting viral maturation.
Tezspire (tezepelumab-ekko) is a human monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), a key epithelial cytokine involved in the initiation and persistence of airway inflammation. By blocking TSLP, tezepelumab reduces the release of pro-inflammatory cytokines and prevents downstream inflammatory responses.
FDA-approved: Treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced adults with multidrug-resistant HIV-1 infection.,Off-label: HIV-1 pre-exposure prophylaxis (Pr EP) in high-risk populations (limited data).
Add-on maintenance treatment of severe asthma in patients aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma
150 mg subcutaneously once every 4 weeks. Initiate with a single loading dose of 150 mg.
210 mg subcutaneously every 4 weeks.
Terminal elimination half-life is approximately 12 hours, supporting once-daily dosing; steady-state is achieved within 2-3 days.
Terminal half-life approximately 26 days, supporting subcutaneous dosing every 4 weeks.
Hepatic via CYP3A4 and CYP2D6; also undergoes UGT1A1-mediated glucuronidation. Tezrul is a moderate inducer of CYP3A4 and a weak inhibitor of CYP2D6.
Tezepelumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolic pathways. No significant hepatic metabolism or CYP450 involvement.
Primarily excreted unchanged in urine via glomerular filtration and active tubular secretion; renal clearance accounts for approximately 80% of total clearance, with fecal elimination as a minor route (~15%).
Tezepelumab is a monoclonal antibody. Clearance occurs via intracellular catabolism. No significant renal or fecal elimination of intact drug. Excretion pathways are not defined by percentage.
Approximately 92% bound to plasma proteins, primarily albumin.
Tezepelumab binds specifically to thymic stromal lymphopoietin (TSLP). Non-specific protein binding is negligible; not bound to plasma proteins.
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid and minimal tissue binding.
Estimated central volume of distribution ~3.9 L (approx. 0.056 L/kg for a 70 kg adult), consistent with limited extravascular distribution.
Subcutaneous: Absolute bioavailability is 75-90% after SC administration, with no significant food effect.
Subcutaneous: Absolute bioavailability not determined; estimated 80-90% based on population pharmacokinetics.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or ESRD; use with caution.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe (Child-Pugh B or C); use with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not approved for use in pediatric patients (safety and efficacy not established).
Not approved for pediatric patients; safety and efficacy not established.
No specific dose adjustment recommended. Limited data in patients ≥65 years; monitor for adverse effects due to potential age-related renal or hepatic decline.
No specific dose adjustment recommended; 210 mg subcutaneously every 4 weeks based on limited data in patients aged 65 years and older.
None
None
Hepatotoxicity: Elevations in liver enzymes have been observed; monitor hepatic function at baseline and periodically.,Lipodystrophy: May cause redistribution/accumulation of body fat.,Immune reconstitution syndrome: Inflammatory response to indolent or residual opportunistic infections.,Drug interactions: Contraindicated with drugs highly dependent on CYP3A4 for clearance, as reduced efficacy may occur.
Hypersensitivity reactions including anaphylaxis have been reported,May increase risk of helminth infections; treat pre-existing helminth infection before initiation,No data on patients with hepatic or renal impairment
Absolute: Coadministration with rifampin, St. John's wort, or certain anticonvulsants (e.g., carbamazepine, phenytoin) due to significant reduction in tezrul exposure.,Relative: Severe hepatic impairment (Child-Pugh class C); use only if benefits outweigh risks.
History of hypersensitivity to tezepelumab or any of its excipients
No specific food interactions reported. Take without regard to meals.
No known food interactions. Tezepelumab-ekko is a monoclonal antibody; food does not affect its absorption or efficacy as it is administered subcutaneously.
First trimester: No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known risks; however, limited human data available. Overall risk cannot be excluded.
Tezepelumab-ekko is a human monoclonal antibody. Ig G antibodies are known to cross the placental barrier increasingly as pregnancy progresses, with the largest amount transferred during the third trimester. There are no adequate and well-controlled studies in pregnant women. Based on animal studies, no evidence of fetal harm was observed in cynomolgus monkeys administered intravenous doses up to 100 mg/kg/week (approximately 42 times the maximum recommended human dose) during organogenesis. However, because animal reproduction studies are not always predictive of human response, tezepelumab should be used during pregnancy only if clearly needed.
Not known if excreted in human milk; M/P ratio not available. Caution recommended; consider developmental and health benefits of breastfeeding along with maternal need for drug.
It is unknown whether tezepelumab-ekko is excreted in human milk. Human Ig G is present in breast milk, but the amount of monoclonal antibody transfer via breast milk is generally limited. The M/P ratio is not available. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tezepelumab and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.
No dosing adjustments recommended; pharmacokinetic changes in pregnancy not established.
No dose adjustment is recommended for tezepelumab-ekko during pregnancy, as pharmacokinetic changes in pregnancy that would necessitate dose adjustments have not been established. The drug is a monoclonal antibody with a long half-life; however, due to increased plasma volume and altered renal function in pregnancy, the clinical significance is unknown. Use only if clearly needed.
Tezrully (tezepelumab-ekko) is a first-in-class thymic stromal lymphopoietin (TSLP) antagonist for severe asthma. Monitor for hypersensitivity reactions, including anaphylaxis. Do not use for acute asthma exacerbations. Administer subcutaneously every 4 weeks; no dose adjustment for renal/hepatic impairment. May reduce exacerbations independent of eosinophil count.
Tezepelumab-ekko is a first-in-class TSLP inhibitor for add-on maintenance therapy of severe asthma. Monitor for hypersensitivity reactions, including anaphylaxis, and advise patients to seek immediate medical care if symptoms occur. Do not discontinue systemic or inhaled corticosteroids abruptly. Live vaccines should not be administered concurrently. Consider pregnancy registry enrollment for exposed patients.
This medication is given as an injection under the skin every 4 weeks.,Do not use to treat sudden asthma attacks; use your rescue inhaler as needed.,Seek immediate medical help if you have signs of allergic reaction like rash, hives, swelling, or trouble breathing.,Store in refrigerator (36-46°F) in original carton; protect from light. Do not freeze or shake.,Tell your healthcare provider about all medicines, including over-the-counter and herbal supplements.,You may not notice immediate improvement; continue regular asthma medications as prescribed.
Tezspire is given as an injection under the skin every 4 weeks by a healthcare provider.,Do not suddenly stop taking other asthma medicines unless instructed by your doctor.,Seek medical help right away if you get a rash, itching, swelling, or trouble breathing after injection.,Tell your doctor if you have a parasitic infection or are taking corticosteroids.,Avoid live vaccines during treatment.
No interactions on record
No interactions on record
Common clinical questions about TEZRULY vs TEZSPIRE, answered by our medical review team.
TEZRULY is a Anti-TSLP Monoclonal Antibody that works by Tezrul is a small molecule inhibitor of the human immunodeficiency virus (HIV) integrase enzyme, blocking the integration of viral DNA into the host genome. It also inhibits the HIV protease enzyme at higher concentrations, disrupting viral maturation.. TEZSPIRE is a Anti-TSLP Monoclonal Antibody that works by Tezspire (tezepelumab-ekko) is a human monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), a key epithelial cytokine involved in the initiation and persistence of airway inflammation. By blocking TSLP, tezepelumab reduces the release of pro-inflammatory cytokines and prevents downstream inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEZRULY and TEZSPIRE depend on the specific clinical indication. These are both Anti-TSLP Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEZRULY is: 150 mg subcutaneously once every 4 weeks. Initiate with a single loading dose of 150 mg.. The standard adult dose of TEZSPIRE is: 210 mg subcutaneously every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEZRULY and TEZSPIRE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEZRULY is classified as Category C. First trimester: No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known risks; however, limited human data ava. TEZSPIRE is classified as Category C. Tezepelumab-ekko is a human monoclonal antibody. IgG antibodies are known to cross the placental barrier increasingly as pregnancy progresses, with the largest amount transferred d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.